# PATH EX

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/path-ex

- Industry: Medical Devices & Equipment
- Headquarters: Houston, US
- Website: www.pathex.co/
- Total disclosed funding: $5M
- Latest round: Seed (Apr 25, 2025)
- Investors on record: 3

## About

PATH EX, Inc. is a Houston-based medical technology company focused on developing innovative blood cleansing devices aimed at diagnosing and managing sepsis, addressing critical healthcare needs with advanced solutions.PATH EX, Inc. specializes in the design of investigational extracorporeal blood cleansing devices. Founded in 2017 in Houston, US, the company has made one significant deal to date. The most recent deal took place on May 8, 2025, when PATH EX raised USD 5.000 mn in venture funding led by IAG Capital Partners, with participation from Fitz Gate Ventures and Texas Medical Center Ventures. The founder of PATH EX has a history in medical technology development, although specific previous ventures are not disclosed.PATH EX specializes in the development of an investigational extracorporeal blood cleansing device aimed at diagnosing and treating sepsis. This innovative device is designed to selectively remove pathogens, such as multi-drug resistant bacteria and endotoxins, from circulating blood, thus addressing critical needs in infection management and critical care. By enabling immediate microbial identification directly from patient samples, it eliminates the need for traditional culturing methods, which can delay treatment. The PATH EX device has demonstrated a significant reduction of over 95 percent in bacterial concentration during a single pass, enhancing the clinical approach to bacteremia and sepsis. The primary users of this technology include healthcare providers in critical care and infectious disease management sectors, primarily within advanced healthcare systems across North America and Europe, where the incidence of sepsis remains a pressing public health challenge.Revenue generation for PATH EX primarily revolves around partnerships and collaborations with healthcare institutions and research organizations rather than direct consumer sales. The company engages in B2B transactions, offering its investigational device to hospitals and healthcare facilities that are involved in critical care and infectious disease treatment. Although specific pricing structures are not disclosed, the device's adoption is likely based on negotiated agreements that reflect the unique needs of each client, including usage fees or equipment leasing arrangements. Given the investigational status of the PATH EX device, revenue streams may also include funding from grants or partnerships with entities focused on advancing medical technology. The company’s focus on a high-impact medical solution positions it within a specialized market, targeting facilities that prioritize innovative approaches to sepsis treatment.In May 2025, PATH EX, Inc. raised USD 5.000 mn in venture funding led by IAG Capital Partners, with participation from Texas Medical Center Ventures and Fitz Gate Ventures. The company will use the funding to support the further enhancement of its CycloPE medical product. PATH EX plans to expand its product lineup with new medical devices targeting infection management and may also explore entering new markets in Asia and South America by 2026.

## Funding rounds

- Seed, Apr 25, 2025, $5M — Texas Medical Center Ventures, Fitz Gate Ventures, IAG Capital Partners

## Investors

- Texas Medical Center Ventures (https://capitalatlas.ai/funds/texas-medical-center-ventures) — Seed
- Fitz Gate Ventures (https://capitalatlas.ai/funds/fitz-gate-ventures) — Seed
- IAG Capital Partners (https://capitalatlas.ai/funds/iag-capital-partners) — Seed